Skip to main content

Patient and physician preferences for anticancer drugs for the treatment of metastatic colorectal cancer: a discrete-choice experiment.

Publication ,  Journal Article
González, JM; Ogale, S; Morlock, R; Posner, J; Hauber, B; Sommer, N; Grothey, A
Published in: Cancer Manag Res
2017

OBJECTIVE: Many publications describe preferences for colorectal cancer (CRC) screening; however, few studies elicited preferences for anticancer-drug treatment for metastatic CRC (mCRC). This study was designed to elicit preferences and risk tolerance among patients and oncologists in the USA for anticancer drugs to treat mCRC. MATERIALS AND METHODS: Patients aged 18 years or older with a self-reported diagnosis of mCRC and board-certified (or equivalent) oncologists who had treated patients with mCRC were recruited by two survey research companies from existing online patient panels in the USA. Additional oncologists were recruited from a list of US physicians. Patients and oncologists completed a discrete-choice experiment (DCE) survey. DCEs offer a systematic method of eliciting preferences and quantifying both the relative importance of treatment attributes and the tradeoffs respondents are willing to make among benefits and risks. Treatment attributes in the DCE were progression-free survival (PFS) and risks of severe papulopustular rash, serious hemorrhage, cardiopulmonary arrest, and gastrointestinal perforation. Patients' and physicians' maximum levels of acceptable treatment-related risks for two prespecified increases in efficacy were estimated. RESULTS: A total of 127 patients and 150 oncologists completed the survey. Relative preferences for the treatment attributes in the study were mostly consistent with the expectation that better clinical outcomes were preferred over worse clinical outcomes. Risk tolerance varied between patients and physicians. On average, physicians were willing to tolerate higher risks than patients, although these differences were mostly not statistically significant. Post hoc latent-class analyses revealed that some patients and physicians were unwilling to forgo any efficacy to avoid toxicities, while others were willing to make such tradeoffs. CONCLUSION: Differences in preferences between patients and physicians suggest that there is the potential for improvement in patients' well-being. Initiating or enhancing discussions about patient tolerance for toxicities, such as skin rash and gastrointestinal perforations, may help prescribe treatments that entail more appropriate benefit-risk tradeoffs.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Cancer Manag Res

DOI

ISSN

1179-1322

Publication Date

2017

Volume

9

Start / End Page

149 / 158

Location

New Zealand

Related Subject Headings

  • 3211 Oncology and carcinogenesis
  • 1112 Oncology and Carcinogenesis
 

Citation

APA
Chicago
ICMJE
MLA
NLM
González, J. M., Ogale, S., Morlock, R., Posner, J., Hauber, B., Sommer, N., & Grothey, A. (2017). Patient and physician preferences for anticancer drugs for the treatment of metastatic colorectal cancer: a discrete-choice experiment. Cancer Manag Res, 9, 149–158. https://doi.org/10.2147/CMAR.S125245
González, Juan Marcos, Sarika Ogale, Robert Morlock, Joshua Posner, Brett Hauber, Nicolas Sommer, and Axel Grothey. “Patient and physician preferences for anticancer drugs for the treatment of metastatic colorectal cancer: a discrete-choice experiment.Cancer Manag Res 9 (2017): 149–58. https://doi.org/10.2147/CMAR.S125245.
González JM, Ogale S, Morlock R, Posner J, Hauber B, Sommer N, et al. Patient and physician preferences for anticancer drugs for the treatment of metastatic colorectal cancer: a discrete-choice experiment. Cancer Manag Res. 2017;9:149–58.
González, Juan Marcos, et al. “Patient and physician preferences for anticancer drugs for the treatment of metastatic colorectal cancer: a discrete-choice experiment.Cancer Manag Res, vol. 9, 2017, pp. 149–58. Pubmed, doi:10.2147/CMAR.S125245.
González JM, Ogale S, Morlock R, Posner J, Hauber B, Sommer N, Grothey A. Patient and physician preferences for anticancer drugs for the treatment of metastatic colorectal cancer: a discrete-choice experiment. Cancer Manag Res. 2017;9:149–158.

Published In

Cancer Manag Res

DOI

ISSN

1179-1322

Publication Date

2017

Volume

9

Start / End Page

149 / 158

Location

New Zealand

Related Subject Headings

  • 3211 Oncology and carcinogenesis
  • 1112 Oncology and Carcinogenesis